Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 259

1.

Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma.

Tsuchiya K, Asahina Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Kurosaki M, Enomoto N, Izumi N.

Liver Transpl. 2014 Mar;20(3):291-7.

PMID:
24734314
2.

Comparison of prognosis by viral etiology in patients with hepatocellular carcinoma after radiofrequency ablation.

Chen PH, Kao WY, Chiou YY, Hung HH, Su CW, Chou YH, Huo TI, Huang YH, Wu WC, Chao Y, Lin HC, Wu JC.

Ann Hepatol. 2013 Mar-Apr;12(2):263-73.

3.

Living donor liver transplantation for hepatocellular carcinoma.

Isik B, Ince V, Karabulut K, Kayaalp C, Yilmaz S.

Transplant Proc. 2012 Jul-Aug;44(6):1713-6. doi: 10.1016/j.transproceed.2012.05.033.

PMID:
22841251
4.

Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.

Kim JM, Kwon CH, Joh JW, Choi MS, Lee JH, Koh KC, Paik SW, Kim GS, Kim SJ, Lee SK, Yoo BC.

Transplant Proc. 2012 Mar;44(2):403-8. doi: 10.1016/j.transproceed.2012.01.067.

PMID:
22410028
5.

Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.

Green TJ, Rochon PJ, Chang S, Ray CE Jr, Winston H, Ruef R, Kreidler SM, Glueck DH, Shulman BC, Brown AC, Durham J.

J Vasc Interv Radiol. 2013 Nov;24(11):1613-22. doi: 10.1016/j.jvir.2013.07.024. Epub 2013 Sep 20.

PMID:
24060436
6.

Percutaneous radiofrequency ablation for early hepatocellular carcinoma: risk factors for survival.

Kikuchi L, Menezes M, Chagas AL, Tani CM, Alencar RS, Diniz MA, Alves VA, D'Albuquerque LA, Carrilho FJ.

World J Gastroenterol. 2014 Feb 14;20(6):1585-93. doi: 10.3748/wjg.v20.i6.1585.

7.

Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy.

Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, Tatsumi C, Ueda T, Minami Y, Ueshima K, Haji S.

Oncology. 2007;72 Suppl 1:98-103. Epub 2007 Dec 13.

PMID:
18087189
8.

Noninvasive fibrosis indices predict intrahepatic distant recurrence of hepatitis B-related hepatocellular carcinoma following radiofrequency ablation.

Seo JY, Kim W, Kwon JH, Jin EH, Yu SJ, Kim HY, Jung YJ, Kim D, Kim YJ, Yoon JH, Lee HS.

Liver Int. 2013 Jul;33(6):884-93. doi: 10.1111/liv.12132. Epub 2013 Mar 5.

PMID:
23461618
9.

Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation?

Chan AC, Chan SC, Chok KS, Cheung TT, Chiu DW, Poon RT, Fan ST, Lo CM.

Liver Transpl. 2013 Apr;19(4):411-9. doi: 10.1002/lt.23605. Epub 2013 Mar 17.

10.

Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.

Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY.

Liver Transpl. 2014 Aug;20(8):945-51. doi: 10.1002/lt.23904. Epub 2014 Jul 12.

12.

Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy.

Chung GE, Kim W, Lee JH, Kim YJ, Yoon JH, Lee JM, Lee JY, Kim SH, Kim D, Lee HS.

J Gastroenterol Hepatol. 2011 Nov;26(11):1638-45. doi: 10.1111/j.1440-1746.2011.06777.x.

PMID:
22011297
13.

AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma.

Yaprak O, Akyildiz M, Dayangac M, Demirbas BT, Guler N, Dogusoy GB, Yuzer Y, Tokat Y.

Hepatobiliary Pancreat Dis Int. 2012 Jun;11(3):256-61.

PMID:
22672818
14.
15.

Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation.

Lai Q, Avolio AW, Graziadei I, Otto G, Rossi M, Tisone G, Goffette P, Vogel W, Pitton MB, Lerut J; European Hepatocellular Cancer Liver Transplant Study Group.

Liver Transpl. 2013 Oct;19(10):1108-18. doi: 10.1002/lt.23706.

16.

Histological differentiation predicts post-liver transplantation survival time.

Li WX, Li Z, Gao PJ, Gao J, Zhu JY.

Clin Res Hepatol Gastroenterol. 2014 Apr;38(2):201-8. doi: 10.1016/j.clinre.2013.11.002. Epub 2013 Dec 30.

PMID:
24388339
17.

Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: a propensity score analysis.

Hsu CY, Huang YH, Chiou YY, Su CW, Lin HC, Lee RC, Chiang JH, Huo TI, Lee FY, Lee SD.

Liver Transpl. 2011 May;17(5):556-66. doi: 10.1002/lt.22273.

18.

Role of radiofrequency ablation in patients with hepatocellular carcinoma who undergo prior transarterial chemoembolization: long-term outcomes and predictive factors.

Sohn W, Choi MS, Cho JY, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Yoo BC.

Gut Liver. 2014 Sep;8(5):543-51. doi: 10.5009/gnl13356. Epub 2014 Jul 25.

19.

Hepatocellular carcinoma downstaging in liver transplantation.

Yu CY, Ou HY, Huang TL, Chen TY, Tsang LL, Chen CL, Cheng YF.

Transplant Proc. 2012 Mar;44(2):412-4. doi: 10.1016/j.transproceed.2012.01.043.

PMID:
22410030
20.

Appropriate treatment strategies for intrahepatic recurrence after curative resection of hepatocellular carcinoma initially within the Milan criteria: according to the recurrence pattern.

Zhang X, Li C, Wen T, Yan L, Li B, Yang J, Wang W, Xu M, Lu W, Jiang L.

Eur J Gastroenterol Hepatol. 2015 Aug;27(8):933-40. doi: 10.1097/MEG.0000000000000383.

PMID:
25933127

Supplemental Content

Support Center